Vistagen’s Fasedienol Misses Primary Endpoint in Phase 3 Social Anxiety Trial but Shows Promise in Severe Cases – Next Steps with FDA Planned
Vistagen Announces Mixed Results from PALISADE-4 Phase 3 Tri...
Sign in to continue:
Vistagen Announces Mixed Results from PALISADE-4 Phase 3 Tri...
Moleculin Biotech, Inc., a pharmaceutical company headquarte...
Easterly Government Properties Closes \$200 Million Term Loa...
Moleculin Biotech, Inc. Announces Positive Preliminary Effic...
Microbot Medical Expands Manufacturing Capacity Through Stra...
Empery Digital Announces \$65 Million Strategic Investment i...
Kennametal Appoints Amanda Cole as Chief Human Resources Off...
SS Innovations Wins Prestigious Outstanding Company Award at...
Southern Alliance Mining Signs Strategic MOU with Malaysia’s...
Kingsmen Creatives Ltd.: Update on Winding Up Proceedings of...